Literature DB >> 6140135

Cytochrome P-450-dependent oxidation of the 17 alpha-ethynyl group of synthetic steroids. D-homoannulation or enzyme inactivation.

S E Schmid, W Y Au, D E Hill, F F Kadlubar, W Slikker.   

Abstract

Metabolism of the 17 alpha-ethynyl group of the synthetic estrogen, 17 alpha-ethynylestradiol, by hepatic microsomes from female rhesus monkeys was studied. Incubation of 17 alpha-ethynylestradiol, labeled with 14C in both ethynyl group carbons, resulted in the formation of D-14C-homoestrone (identified by high performance liquid chromatography and gas chromatography-mass spectrometry) and 14CO2. The D-homoestrone appears to be formed by a rearrangement in which one ethynyl group carbon is incorporated into the D ring of the steroid (D-homoannulation) and the second is subsequently removed as CO2. Cofactor, inhibition, and subcellular fractionation studies on the rate of 14CO2 formation showed that the ethynyl group is oxidized by cytochrome P-450. Hepatic microsomes isolated from rhesus monkeys treated with phenobarbital, but not 3-methylcholanthrene or pregnenelone-16 alpha-carbonitrile, resulted in increased rates of 14CO2 formation. Oxidation of the 17 alpha-ethynyl group is postulated to produce a high energy intermediate which is rearranged by D-homoannulation. However, as an alternative reaction, this unstable intermediate might covalently bind and inactivate the cytochrome P-450 enzymes catalyzing its formation. In support of this hypothesis, both cytochrome P-450 concentrations and the rate of catalysis of the D-homoannulation pathway by this enzyme were significantly decreased in hepatic microsomes from rhesus monkeys which had been administered mestranol and/or ethynerone (17 alpha-ethynylated steroids) at dosage levels mimicking human exposure to oral contraceptive agents.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6140135

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  9 in total

Review 1.  Rearrangement reactions catalyzed by cytochrome P450s.

Authors:  Paul R Ortiz de Montellano; Sidney D Nelson
Journal:  Arch Biochem Biophys       Date:  2010-10-29       Impact factor: 4.013

Review 2.  Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug.

Authors:  Hongjian Zhang; Donghui Cui; Bonnie Wang; Yong-Hae Han; Praveen Balimane; Zheng Yang; Michael Sinz; A David Rodrigues
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 3.  Formation and Cleavage of C-C Bonds by Enzymatic Oxidation-Reduction Reactions.

Authors:  F Peter Guengerich; Francis K Yoshimoto
Journal:  Chem Rev       Date:  2018-06-22       Impact factor: 60.622

Review 4.  Acetylenes: cytochrome P450 oxidation and mechanism-based enzyme inactivation.

Authors:  Paul R Ortiz de Montellano
Journal:  Drug Metab Rev       Date:  2019-07-07       Impact factor: 4.518

5.  Identification of 17-alpha-ethynylestradiol-modified active site peptides and glutathione conjugates formed during metabolism and inactivation of P450s 2B1 and 2B6.

Authors:  Ute M Kent; Hsia-Lien Lin; Danielle E Mills; Kelly A Regal; Paul F Hollenberg
Journal:  Chem Res Toxicol       Date:  2006-02       Impact factor: 3.739

6.  Target organ-specific inactivation of drug metabolizing enzymes in kidney of hamsters treated with estradiol.

Authors:  D Roy; J G Liehr
Journal:  Mol Cell Biochem       Date:  1992-03-04       Impact factor: 3.396

7.  Suicidal destruction of cytochrome p-450 by ethynyl substituted compounds.

Authors:  I N White
Journal:  Pharm Res       Date:  1984-07       Impact factor: 4.200

Review 8.  Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.

Authors:  Shufeng Zhou; Sui Yung Chan; Boon Cher Goh; Eli Chan; Wei Duan; Min Huang; Howard L McLeod
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

9.  Inhibiting effect of ethinylestradiol/levonorgestrel combination on microsomal enzymatic activities in rat liver and kidney.

Authors:  P Czekaj; G Nowaczyk-Dura
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1999 Jul-Sep       Impact factor: 2.569

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.